Literature DB >> 8983363

[Efficiency of bone marrow aspirate for diagnosis of opportunistic infections in HIV infected patients].

A Supervía1, H Knobel, E Pérez-Vila, M E Abellá, M Salvado, L Mellibovsky, A Díez.   

Abstract

AIDS is the first cause of opportunistic infections. The objective of the present study was the evaluation of the efficiency of bone marrow aspirate (BMA) for diagnosis of opportunistic infections in HIV infected patients with prolonged fever. Charts from 92 patients with BMA from 1992 to 1994 were reviewed. Diagnosis was achieved in 14.1% of cases. Diagnosis cannot be made by other methods in six leishmaniasis and in two disseminated tuberculosis. The sensibility was of 33.3% for mycobacterial infections, the sensibility of hemoculture was of 50%. The hemoglobin level was lower for patients with diagnostic BMA than for patients with not diagnostic BMA (77 g/l vs 97 g/l, p < 0.0004). The WBC counts was not different in both groups of patients, and platelets counts was greater in patients with BMA diagnostic (165 x 10(9)/l vs 102 x 10(9)/l, p < 0.001). In the patients with hemoglobin lower than 100 g/l the diagnostic efficiency was 18.6% (11 of 59 cases). The BMA was unprofitable in HIV infected patients with prolonged fever without hemocytopenias. Profitability increase in patients with hemoglobin lower than 100 g/l. The BMA in useful for leishmania identification. The hemoculture has greater sensitivity than BMA for the diagnosis of mycobacterial disseminated infection.

Entities:  

Mesh:

Year:  1996        PMID: 8983363

Source DB:  PubMed          Journal:  An Med Interna        ISSN: 0212-7199


  1 in total

1.  Mycobacterium tuberculosis complex bacteremia among HIV and non-HIV patients in a Mexican tertiary care center.

Authors:  Karla Maria Tamez-Torres; Pedro Torres-Gonzalez; Miguel E Cervera-Hernandez; Barbara Chavez-Mazari; Corazon de Jesus Barrientos-Flores; Miriam Bobadilla-Del-Valle; Alfredo Ponce-de-Leon; Jose Sifuentes-Osornio
Journal:  Braz J Infect Dis       Date:  2018-10-30       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.